Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
BM Scirica, DL Bhatt, E Braunwald… - … England Journal of …, 2013 - Mass Medical Soc
Background The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
[PDF][PDF] Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
BM Scirica, DL Bhatt, E Braunwald, PG Steg… - N Engl J Med, 2013 - academia.edu
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Page 1 The
new england journal of medicine n engl j med 369;14 nejm.org october 3, 2013 1317 original …
new england journal of medicine n engl j med 369;14 nejm.org october 3, 2013 1317 original …
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
BM Scirica, DL Bhatt, E Braunwald, PG Steg… - The New England …, 2013 - research.rug.nl
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
BM Scirica, DL Bhatt, E Braunwald, PG Steg… - The New England …, 2013 - europepmc.org
Background The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
B Scirica, D Bhatt, E Braunwald, P Steg… - NEW ENGLAND …, 2013 - boa.unimib.it
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
BM Scirica, DL Bhatt… - New England …, 2013 - utsouthwestern.elsevierpure.com
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
SAVOR-TIMI 53 Steering Committee and … - New England Journal …, 2013 - cris.bgu.ac.il
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
BM Scirica, DL Bhatt, E Braunwald… - The New England …, 2013 - pubmed.ncbi.nlm.nih.gov
Background The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
[引用][C] Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
BM SCIRICA, DL BHATT… - The New England …, 2013 - pascal-francis.inist.fr
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
B Scirica, D Bhatt, E Braunwald, P Steg… - NEW ENGLAND …, 2013 - research.unipd.it
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …